{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:22:04Z","timestamp":1761841324880},"reference-count":35,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[1995,5,1]],"date-time":"1995-05-01T00:00:00Z","timestamp":799286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World j. surg."],"published-print":{"date-parts":[[1995,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Response to and survival after hyperthermic isolated limb perfusion (HILP) with melphalan in patients with malignant melanoma at the Royal Brisbane Hospital were reviewed in order to assess the major determinants of response to treatment. Data were collected by clinical chart review and direct patient contact. Response was assessed by clinical observation and measurement of nodules. Survival was calculated from the date of perfusion to the date of patient death. Since 1965 there have been 85 patients (38\u00a0men, 47 women) who have undergone 109 limb (102 leg, 7 arm) perfusions. The mean age was 58 years (range 32\u201382 years). The number of patients per disease stage (M.D. Anderson classification) was as follows: stage I, 5 patients; stage II, 8 patients; stage IIIa, 41 patients; stage IIIab, 25 patients; and stage IIIb, 8 patients. The mean duration of perfusion was 81\u00a0minutes. Melphalan was given in divided doses, with a mean total dose 1.39\u00a0mg\/kg. The mean maximal limb temperature was 41.5\u00b0C. Major complications occurred during 20 perfusions (18%). There was one postoperative death from myocardial infarction, and one patient required amputation. Median patient follow\u2010up was 2.65 years (range 1\u201327 years). A complete response was noted in 34 patients (40%), a partial response in 36 patients (42%), and no response in 11 patients (13%). response could not be assessed in four patients. The actuarial 5\u2010year survival for the whole group was 45%: stage I, 80%; stage II, 75%; stage IIIa, 44%; stage IIIab, 23%; stage IIIb, 56%. The two significant determinants of response to perfusion were disease stage (<jats:italic>p<\/jats:italic>=0.00005) and nodal status (<jats:italic>p<\/jats:italic>=0.03). The major determinant of survival was a complete perfusion response (<jats:italic>p<\/jats:italic>=0.0012). Less advanced disease responds better to perfusion and is associated with increased survival after perfusion.<\/jats:p>","DOI":"10.1007\/bf00299159","type":"journal-article","created":{"date-parts":[[2004,10,6]],"date-time":"2004-10-06T17:14:42Z","timestamp":1097082882000},"page":"363-368","source":"Crossref","is-referenced-by-count":29,"title":["Hyperthermic isolated limb perfusion for malignant melanoma: Response and survival"],"prefix":"10.1002","volume":"19","author":[{"given":"Peter J.","family":"Bryant","sequence":"first","affiliation":[{"name":"Department of Surgery Royal Brisbane Hospital University of Queensland 4029 Herston Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenda A.","family":"Balderson","sequence":"additional","affiliation":[{"name":"Department of Surgery Royal Brisbane Hospital University of Queensland 4029 Herston Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Mead","sequence":"additional","affiliation":[{"name":"Department of Surgery Royal Brisbane Hospital University of Queensland 4029 Herston Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William S.","family":"Egerton","sequence":"additional","affiliation":[{"name":"Department of Surgery Royal Brisbane Hospital University of Queensland 4029 Herston Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[1995,5]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01658878"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02071527"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1989.01410030123020"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930520411"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1990.01410150039008"},{"key":"e_1_2_1_7_1","first-page":"339","article-title":"Results of hyperthermic perfusion for melanoma of the extremities","volume":"140","author":"Stehlin J.S.","year":"1975","journal-title":"Surg. Gynecol. Obstet."},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9610(85)90006-6"},{"key":"e_1_2_1_9_1","first-page":"133","article-title":"Chemotherapy by regional perfusion for limb melanoma","volume":"53","author":"Krementz E.T.","year":"1987","journal-title":"Am. Surg."},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01655819"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930420315"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800770716"},{"key":"e_1_2_1_13_1","unstructured":"Lejeune F. Krementz E. Vaglini M.(study coordinators):Protocol\u2014EORTC Malignant Melanoma Co\u2010operative Group North American Perfusion Group and WHO Collaborating Centres for evaluation of methods of diagnosis and treatment of melanoma: a randomized trial on prophylactic isolated perfusion for stage I high risk (>1.5 mm thickness) malignant melanoma of the limbs. March 1984."},{"key":"e_1_2_1_14_1","first-page":"616","article-title":"Chemotherapy of cancer: regional perfusion utilizing an extra\u2010corporeal circuit","volume":"148","author":"Creech O.","year":"1958","journal-title":"Am. Surg."},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1980.tb134628.x"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/84.18.1427"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.1982.tb00739.x"},{"key":"e_1_2_1_18_1","volume-title":"Malignant Skin Tumours","author":"O'Rourke M.G.E.","year":"1991"},{"key":"e_1_2_1_19_1","first-page":"236","volume-title":"Malignant Skin Tumours","author":"Egerton W.S.","year":"1991"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02071525"},{"key":"e_1_2_1_21_1","first-page":"157","article-title":"Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics","volume":"14","author":"Benckhuijsen C.","year":"1988","journal-title":"Eur. J. Surg. Oncol."},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(82)90235-8"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1992.235"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.12.2091"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-82025-0_39"},{"key":"e_1_2_1_26_1","first-page":"471","article-title":"Regional perfusion in the treatment of locally metastasized malignant melanoma of the limbs","volume":"17","author":"Oldhoff M.H.","year":"1981","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890615)63:12<2551::AID-CNCR2820631233>3.0.CO;2-7"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850601)55:11<2638::AID-CNCR2820551118>3.0.CO;2-E"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930360305"},{"key":"e_1_2_1_30_1","first-page":"1031","article-title":"Isolated limb perfusion for malignant melanoma","volume":"224","author":"Rosin R.D.","year":"1980","journal-title":"Practitioner"},{"key":"e_1_2_1_31_1","first-page":"101","article-title":"Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future","volume":"14","author":"Kroon B.B.R.","year":"1988","journal-title":"Eur. J. Surg. Oncol."},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19860201)57:3<416::AID-CNCR2820570304>3.0.CO;2-M"},{"key":"e_1_2_1_33_1","first-page":"39","article-title":"Prognostic factors for tumour response and limb recurrence\u2010free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan","volume":"115","author":"Klaase J.M.","year":"1994","journal-title":"Surgery"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02071526"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(05)80163-7"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.7.1022"}],"container-title":["World Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00299159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00299159\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1007\/BF00299159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T15:35:09Z","timestamp":1703691309000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1007\/BF00299159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,5]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1995,5]]}},"alternative-id":["10.1007\/BF00299159"],"URL":"https:\/\/doi.org\/10.1007\/bf00299159","archive":["Portico"],"relation":{},"ISSN":["0364-2313","1432-2323"],"issn-type":[{"value":"0364-2313","type":"print"},{"value":"1432-2323","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,5]]}}}